Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib
A case report
Koki Nakashima, MDa,b,∗, Yoshiki Demura, MD, PhDa, Kosuke Kurokawa, MDa, Toshihiro Takeda, MDa, Norihiro Jikuya, MDa, Masahiro Oi, MDa, Toshihiko Tada, MDa, Masaya Akai, MD, PhDa, Tamotsu Ishizuka, MD, PhDb

Abstract
Rationale: Although anaplastic lymphoma kinase (ALK) inhibitors are effective treatment options for ALK-positive non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastasis, achieving long-term survival in patients with NSCLC with meningeal carcinomatosis resistant to ALK inhibitors is difficult. Lorlatinib, a third-generation ALK inhibitor, was designed for selective CNS penetration, and exerts potent antitumor activity against tumors resistant to first- and/or second-generation ALK inhibitors. However, there is limited information about the activity of lorlatinib in ALK inhibitor-resistant meningeal carcinomatosis. Here, we report a case of ALK-positive lung adenocarcinoma with meningeal carcinomatosis in which lorlatinib was used after resistance to alectinib and brigatinib.

Patients concerns: A 55-year-old woman with no history of smoking presented to our hospital with a swelling on the left neck. Clinical imaging and histopathological examination revealed a tumor of adenocarcinoma histology in the left upper lung with no CNS metastasis.

Diagnoses: The patient was diagnosed with ALK-positive lung adenocarcinoma (cT3N3M1b: stage IVA).

Interventions: She received the second-generation ALK inhibitors, alectinib and brigatinib, in the first and second-line settings, respectively. However, she developed meningeal carcinomatosis. Hence, treatment with lorlatinib was initiated in the third-line setting.

Outcomes: The symptoms associated with meningeal carcinomatosis, such as disturbance of consciousness and diplopia, improved dramatically. At 8 months from the initiation of lorlatinib, the patient remained well without disease progression.

Lessons: Lorlatinib is an effective treatment option for patient with ALK-positive NSCLC who develop meningeal carcinomatosis resistant to second-generation ALK inhibitors. Therefore, lorlatinib should be considered in such cases, even when patients exhibit serious symptoms associated with meningeal carcinomatosis.

Abbreviations: ALK = anaplastic lymphoma kinase, CNS = central nervous system, EGFR = epidermal growth factor receptor, MRI = magnetic resonance imaging, NSCLC = non-small cell lung cancer, TKI = tyrosine kinase inhibitor.

Keywords: anaplastic lymphoma kinase, case report, lorlatinib, meningeal carcinomatosis, non-small cell lung cancer

Editor: Maya Saranathan.
The authors have no conflicts of interests to disclose.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

© 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Nakashima K, Demura Y, Kurokawa K, Takeda T, Jikuya N, Oi M, Tada T, Akai M, Ishizuka T. Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: a case report. Medicine 2021;100:39(e27385).

http://dx.doi.org/10.1097/MD.00000000000027385

Received: 14 July 2021 / Received in final form: 25 August 2021 / Accepted: 15 September 2021
1. Introduction

Meningeal carcinomatosis is a severe condition associated with poor prognosis in patients with non-small cell lung cancer (NSCLC). Based on previous studies, patients without driver oncogenes have demonstrated a median overall survival of about 1.4 to 5.9 months from diagnosis.[1,2] Contrarily, for patients with NSCLC harboring driver oncogenes who develop meningeal carcinomatosis, molecularly targeted drugs, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and anaplastic lymphoma kinase (ALK) inhibitors, have been shown to be effective treatment options.[1–4] However, achieving long-term survival in patients with meningeal carcinomatosis resistant to these drugs is difficult.

Lorlatinib, a third-generation ALK inhibitor, was designed for selective central nervous system (CNS) penetration.[5,6] Lorlatinib exerts potent antitumor activity against tumors that are resistant to first- and/or second-generation ALK inhibitors.[7,8] Therefore, lorlatinib could be an effective treatment option for patients with ALK-positive NSCLC with CNS metastasis, who have been previously treated with ALK inhibitors. However, there is limited information about the activity of lorlatinib in ALK inhibitor-resistant meningeal carcinomatosis.

We report a patient with ALK-positive lung adenocarcinoma who developed meningeal carcinomatosis after treatment with alectinib and brigatinib.

2. Case presentation

The patient gave his informed consent for the publication of the details concerning his case, including images.

A 55-year-old woman without a history of smoking presented to our hospital with a swelling in the left neck. Computed tomography revealed a tumor in the left upper lung, swelling of the left supraclavicular lymph nodes, multiple mediastinal lymph nodes, and liver metastasis. Contrast-enhanced magnetic resonance imaging (MRI) of the brain revealed no CNS metastasis. Pathological examination of the endobronchial ultrasound-guided transbronchial needle aspiration of lymph node #7 revealed adenocarcinoma histology. Immunohistochemistry and fluorescence in situ hybridization revealed that the tumor was positive for ALK. Based on these findings, a diagnosis of ALK-positive lung adenocarcinoma (cT3N3M1b: stage IVA) was established.

Alectinib (600 mg/day) was initiated as first-line treatment, and it resulted in a partial response. There were no adverse effects associated with the use of alectinib. However, tumor progression was observed 20 months after the initiation of alectinib. Therefore, brigatinib (180 mg/day) was initiated as second-line treatment, resulting in a partial response. There were no adverse effects associated with the use of brigatinib. However, disturbance of consciousness and diplopia occurred 30 months after the initiation of brigatinib. Contrast-enhanced magnetic resonance imaging (MRI) of the brain revealed no CNS metastasis. Pathological examination of the endobronchial ultrasound-guided transbronchial needle aspiration of lymph node #7 revealed adenocarcinoma histology. Immunohistochemistry and fluorescence in situ hybridization revealed that the tumor was positive for ALK. Based on these findings, a diagnosis of ALK-positive lung adenocarcinoma (cT3N3M1b: stage IVA) was established.

Alectinib (600 mg/day) was initiated as first-line treatment, and it resulted in a partial response. There were no adverse effects associated with the use of alectinib. However, tumor progression was observed 20 months after the initiation of alectinib. Therefore, brigatinib (180 mg/day) was initiated as second-line treatment, resulting in a partial response. There were no adverse effects associated with the use of brigatinib. However, disturbance of consciousness and diplopia occurred 30 months after the initiation of brigatinib. Contrast-enhanced MRI of the brain revealed a diffuse and linear enhancement along the cerebellar folia (Fig. 1). Examination of the cerebrospinal fluid showed 34 white blood cells /μL (mononuclear cells 95%, polymuclear cells 1%, others 4%), a protein value of 105 mg/dL, and a glucose level of 44 mg/dL. Adenocarcinoma was confirmed by cerebrospinal fluid examination. Based on these findings, a diagnosis of meningeal carcinomatosis was established, and the disturbance of consciousness and diplopia were considered to be its associated symptoms.

Treatment with lorlatinib (100 mg/day) was initiated in the third-line setting, and the patient’s disturbance of consciousness and diplopia improved dramatically. Contrast-enhanced MRI of the brain revealed that the diffuse and linear enhancement along the cerebellar folia had disappeared (Fig. 2). There were no adverse effects associated with the use of lorlatinib. At 8 months from the initiation of treatment with lorlatinib, the patient remained well without disease progression.

Figure 1. Brain contrast-enhanced magnetic resonance imaging when a disturbance of consciousness and diplopia occurred, shows diffuse, and linear enhancement along the cerebellar folia (arrows).

Figure 2. Brain contrast-enhanced magnetic resonance imaging after 3 months after the initiation of lorlatinib shows improvement of the diffuse and linear enhancement along the cerebellar folia.
3. Discussion

The prognosis of patients with NSCLC who develop meningeal carcinomatosis without driver oncogenes remains poor.\cite{1,2} ALK inhibitors are an effective treatment option for patient with ALK-positive NSCLC who develop meningeal carcinomatosis.\cite{4} However, the successful treatment of ALK-positive NSCLC with ALK-inhibitor-resistant meningeal carcinomatosis has not yet been reported in the literature. To the best our knowledge, this is the first report of successful treatment with lorlatinib in a patient who responded poorly to alectinib and brigatinib.

The efficacy of lorlatinib in the present case was influenced by 2 factors. First, lorlatinib is highly effective for treating patients with CNS metastasis since it was designed to cross the blood-brain barrier to achieve high CNS exposure.\cite{5} Chen et al\cite{6} have shown that the brain tissue partition coefficient of lorlatinib is 0.7, indicating high CNS exposure. Wang et al\cite{9} reported that lorlatinib was clinically the most effective ALK inhibitor against CNS metastasis among lorlatinib, alectinib, brigatinib, and crizotinib. In patients with EGFR mutation-positive NSCLC who develop meningeal carcinomatosis, osimertinib has been reported to be the most beneficial treatment option.\cite{11} Several studies have also shown that osimertinib has greater CNS penetration and higher brain exposure than other EGFR-TKIs.\cite{10} These results indicate that CNS penetration is an important factor in the treatment of meningeal carcinomatosis with molecularly targeted drugs. In the present case, the high intracranial penetration of lorlatinib likely affected the intracranial metastasis, even though the tumor progressed with brigatinib.

Second, lorlatinib is effective against tumors that are resistant to first-, and second-generation ALK inhibitors. Lorlatinib acts against all known ALK resistance mutations.\cite{11,12} Several clinical trials have shown that lorlatinib is effective in ALK-positive NSCLC patients with secondary ALK resistance mutations.\cite{8,13} As seen in the present case, lorlatinib is effective for tumors that are resistant to second-generation ALK inhibitors, such as alectinib and brigatinib.

The present report indicates that lorlatinib is an effective treatment option for patient with ALK-positive NSCLC who develop meningeal carcinomatosis resistant to second-generation ALK inhibitors.

4. Conclusion

Here we have reported the successful treatment with lorlatinib of a patient with ALK-positive NSCLC who develop meningeal carcinomatosis. Our results suggest that lorlatinib could be considered in patients with meningeal carcinomatosis resistant to second-generation ALK inhibitors, even when they exhibit serious symptoms associated with meningeal carcinomatosis.

Acknowledgments

We would like to thank Editage (www.editage.com) for providing English language editing assistance.

Author contributions

Conceptualization: Koki Nakashima, Yoshiki Demura.

Data curation: Yoshiki Demura.

Resources: Yoshiki Demura.

Supervision: Tamotsu Ishizuka.

Validation: Koki Nakashima.

Visualization: Koki Nakashima, Yoshiki Demura.

Writing – original draft: Koki Nakashima, Yoshiki Demura.

Writing – review & editing: Kosuke Kurokawa, Toshihiro Takeda, Norihiro Jikuya, Masahiro Oi, Toshihiko Tada, Masaya Akai, Tamotsu Ishizuka.

References

\[1\] Umemura S, Tsubouchi K, Yoshioka H, et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer 2012;77:134–9.

\[2\] Xu Y, Hu M, Zhang M, et al. Prospective study revealed prognostic significance of responses in leptomeningeal metastases and clinical value of cerebrospinal fluid-based liquid biopsy. Lung Cancer 2018;125:142–9.

\[3\] Yang JCH, Kim SW, Kim DW, et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol 2020;38:538–47.

\[4\] Gaye E, Geier M, Bore P, et al. Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis. Lung Cancer 2019;133:1–3.

\[5\] Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4- (metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem 2014;57:4720–44.

\[6\] Chen W, Jin D, Shi Y, Zhang Y, Zhou H, Li G. The underlying mechanisms of lorlatinib penetration across the blood-brain barrier and the distribution characteristics of lorlatinib in the brain. Cancer Med 2020;9:4350–9.

\[7\] Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 2017;18:1590–9.

\[8\] Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol 2018;19:1654–67.

\[9\] Wang L, Sheng Z, Zhang J, et al. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/ununtreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis. J Chemother 2021:1–10. Online ahead of print.

\[10\] Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-Mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 2016;22:5130–40.

\[11\] Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 2016;6:1118–33.

\[12\] Horn L, Whisentant JT, Wakelee H, et al. Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. J Thorac Oncol 2019;14:1901–11.

\[13\] Shaw AT, Solomon BJ, Besse B, et al. ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J Clin Oncol 2019;37:1370–9.

[3]